AAA
MAZE

Affinity Asset Advisors’s Maze Therapeutics MAZE Stock Holding History

Affinity Asset Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-250,000
Closed -$2.75M – 119
2025
Q1 		$2.75M Buy
+250,000
New +$3.01M 0.26% 57

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Affinity Asset Advisors's MAZE Position: Q2 2025 in Review

Affinity Asset Advisors sold out of Maze Therapeutics (MAZE) in Q2 2025, closing a stake of 250,000 shares — an estimated $2.75M sold.

Affinity Asset Advisors first reported a position in MAZE in Q1 2025 and held it in 1 quarter. The position peaked at $2.75M in Q1 2025. 75 funds tracked by Wall St. Rank hold MAZE as of Q2 2025.

  • Affinity Asset Advisors reported no remaining Maze Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 Maze Therapeutics shares in Q2 2025, an estimated $2.75M.
  • Affinity Asset Advisors first reported a position in Maze Therapeutics in Q1 2025 and held it in 1 quarter.
  • Affinity Asset Advisors's Maze Therapeutics position peaked at $2.75M in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2025.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.